Drug Discovery · Saint Louis, MO · Founded 2018 · Privately Held (backing)
Developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers. Wugen is based in Saint Louis, MO and was founded in 2018. It is valued at about $215 million as of Oct 2026, set by institutional fund marks, down 12% since its later-stage round in Aug 2025. It has raised $323 million across 2 recorded rounds; the latest was an $115 million Series C in Aug 2025.
PMV mark · valuation
$214.5M
Oct 2026
Since last round
-12%
Aug 2025
Total raised
$323.0M
Last round
Later Stage VC (Series C)
Aug 2025
No prints on record
No secondary trades in Wugen shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Wugen stock.
